Introduction: Benzodiazepines are prescribed inappropriately in up to 40% of outpatients. The purpose of this study is to describe a collaborative team-based care model in which clinical pharmacists work with primary care providers (PCPs) to improve the safe use of benzodiazepines for anxiety and sleep disorders and to assess the preliminary results of the impact of the clinical service on patient outcomes. Methods: Adult patients were eligible if they received care from the academic primary care clinic, were prescribed a benzodiazepine chronically, and were not pregnant or managed by psychiatry. Outcomes included baseline PCP confidence and knowledge of appropriate benzodiazepine use, patient symptom severity, and medication changes. Results: Twenty-five of 57 PCPs responded to the survey. PCPs reported greater confidence in diagnosing and treating generalized anxiety and panic disorders than sleep disorder and had variable knowledge of appropriate benzodiazepine prescribing. Twenty-nine patients had at least 1 visit. Over 44 total patient visits, 59% resulted in the addition or optimization of a nonbenzodiazepine medication and 46% resulted in the discontinuation or optimization of a benzodiazepine. Generalized anxiety symptom severity scores significantly improved (À2.0; 95% confidence interval (CI): À3.57 to À0.43). Conclusion: Collaborative team-based models that include clinical pharmacists in primary care can assist in optimizing high-risk benzodiazepine use. Although these findings suggest improvements in safe medication use and symptoms, additional studies are needed to confirm these preliminary results.
Introduction
Benzodiazepines are prescribed chronically for 14% to 31% of US adults 1 and inappropriately prescribed to 12% to 40% of older adults in the outpatient setting. 2 The number of benzodiazepine prescriptions has tripled in recent years, with an accompanying 4-fold increase in benzodiazepine-related overdose deaths. 3 The high rate of benzodiazepine use represents a major patient safety concern, given benzodiazepines are associated with an increased risk of abuse, falls, asthenia, impaired cognition and memory, and the potential to worsen or precipitate anxiety if not dosed appropriately. 4 Further, the direct medical cost of injuries from benzodiazepine use among a sample of 17 558 patients over 2 years was estimated to be US$3.3 million. 5 Of those injuries that led to hospitalization, each event costs nearly US$10 000. 5 Thus, more judicious use of benzodiazepines could help avoid costly and preventable injuries. 5 Due to these safety concerns, clinical practice guidelines recommend benzodiazepine use only for the treatment of limited conditions. 6 Appropriate psychiatric indications for benzodiazepines include acute treatment of panic attacks or specific/situational anxiety and scheduled (around the clock) use for other refractory anxiety and sleep disorders. [6] [7] [8] [9] However, benzodiazepines continue to be prescribed first line in many patient scenarios and estimates indicate their use continues to increase. 10 Barriers to appropriate benzodiazepine use include provider unfamiliarity with best practices and pressure from patients. 7 Although most providers are aware of some risks associated with benzodiazepine use, many are not aware of all the risks. 8 Providers also do not have time to educate their patients on the potential risks of benzodiazepine use or to transition them to more appropriate therapies that may be safer. 8 Ideally, mental health specialists would manage patients prescribed benzodiazepines who have complex medical or psychiatric conditions, but many patients cannot access specialty care due to the current shortage of mental health providers. As a result, these patients are utilizing their primary care providers (PCPs) for their mental health needs. 11 PCPs prescribe 55% of all benzodiazepines 12 and 90% of all chronic benzodiazepines for older adults. 1 In primary care, benzodiazepines are largely prescribed for insomnia (42%) and anxiety (36%). 13 This demand for more PCP time to address such mental health needs is met with primary care shortages and already overburdened PCPs. 14, 15 Collaboration with clinical pharmacists integrated in primary care clinics could assist overburdened PCPs to optimize benzodiazepine use. Managing chronic disease states under collaborative agreements, clinical pharmacists can serve as extenders of PCPs by saving them time that they can spend on other patient issues that require their medical expertise. 16, 17 Such a teambased approach would support appropriate use of benzodiazepines and initiation of alternate, preferred therapies when possible. 18 Collaborative team-based care models are considered the gold standard for managing patients with mental health conditions, including anxiety, and models involving health-care professionals other than pharmacists have demonstrated improvements in appropriate benzodiazepine use. 19 As the medication experts, clinical pharmacists are well positioned to collaborate with an interdisciplinary team of PCPs to optimize appropriate benzodiazepine use, improve patient safety, and improve anxiety symptom control. [18] [19] [20] Although studies have clearly described the benefits of pharmacists collaborating to improve suboptimal medication use and outcomes in many settings, 17, 18, [21] [22] [23] [24] none have assessed the impact of pharmacists integrated in primary care working to improve high-risk benzodiazepine use. Therefore, the purpose of this article is to describe a collaborative team-based care model in which clinical pharmacists work with PCPs to improve the safe use of benzodiazepines for anxiety and sleep disorders and to assess the preliminary results of the impact of the clinical service on patient outcomes.
Methods
Our primary objective is to describe the benzodiazepine service. Secondary objectives are to describe the needs assessment results that supported the implementation of the service and preliminary efficacy outcomes.
Practice Setting and Description of Clinical Pharmacy Team
The Anschutz Internal Medicine Clinic at the University of Colorado Hospital included an interdisciplinary team comprised of 25 physicians, 1 nurse practitioner, 2 physician assistants, and 1 clinical pharmacist. The clinic also included medical and pharmacy students, residents, and fellows. The clinic cares for approximately 18 000 unique patients, accounting for about 34 000 patient visits annually. Patient payer source is 4% Medicaid, 23% Medicare, and 70% commercial. Prior to the implementation of the benzodiazepine service, a clinical pharmacist performed a chart review on a random sample of the clinic's patients taking benzodiazepines. The chart review suggested that 21% of patients prescribed a benzodiazepine were prescribed a benzodiazepine inappropriately, which supported the need for the service. Inappropriate use was identified as ''as-needed'' use for anything other than panic attack, specific phobia, or situational anxiety; scheduled use as first-line treatment for anxiety/ sleep disorders; or undocumented evidence of failure to preferred, safer alternatives for the indication.
The clinic's integrated clinical pharmacy team included an attending pharmacist and pharmacy students, primary care track residents, and a fellow. The pharmacy team manages medications for chronic medical conditions under collaborative practice agreements, referred to by State Board of Pharmacy as collaborative drug therapy management (CDTM) protocols. Under CDTM, the pharmacists are able to prescribe medications and order laboratory assessments. All patient visits with the pharmacy team occurred in the clinic, followed the layered learning model, and were conducted similar to other PCP visits. All patients were seen by appointment only, and visits were supported by the clinic staff who roomed the patients and took vitals. Given current national reimbursement restrictions, only facility fees were billed and reimbursed for the visits with the pharmacy team. Patients were responsible for any co-pays or premiums required by their medical insurance related to the visit. Each visit with the pharmacy team was supervised and staffed by the attending clinical pharmacist.
Patient Identification and Referrals to the Pharmacy Team
An electronic registry of patients generated from the electronic health record (EHR) assisted in the identification of patients eligible for the benzodiazepine service. Patients were eligible if they were at least 18 years old, received primary care at the clinic, and were prescribed a benzodiazepine for at least 3 months for an anxiety disorder or sleep disturbance. Pregnant women and patients managed by psychiatry were not eligible for participation in the benzodiazepine service. Because asneeded benzodiazepines were often prescribed, the pharmacy team also performed chart reviews to confirm eligibility.
Patients identified as eligible by the pharmacy team had referral orders pended for PCPs to accept or reject by the clinic staff. Acceptance or approval of a referral order served as the authorization for pharmacy to manage benzodiazepines and medications for anxiety and sleep disturbance under CDTM protocol. Upon referral approval, the pharmacy team outreached the patient by phone and invited them to participate in the benzodiazepine service. Initially, the outreach was conducted by clinic staff but was transitioned to the pharmacy team, given the staff had difficulty communicating effectively with patients about the potentially sensitive nature of the discussion. A standardized phone script was used to guide the outreach discussions.
Baseline Needs Assessment and Education
Prior to the launch of the benzodiazepine service, PCPs were asked to complete a baseline survey to assess knowledge of benzodiazepine use. The 12-item survey was created and underwent cognitive testing with 8 PCPs. It included demographic questions, and 8 questions related to provider understanding of appropriate benzodiazepine use. The survey was distributed electronically using Qualtrics survey software over 2 weeks to all PCPs in the clinic, including medical residents. The results of the survey were used to develop an educational session for the PCPs and were used as a needs assessment for the implementation of the benzodiazepine service.
PCPs received a one-time, formal, evidence-based review session guided by the CDTM treatment algorithms and the needs identified in the survey during a faculty meeting. Indirect education also occurred through review of the pharmacy team's documentation within the EHR and informal conversations regarding therapeutic decisions for patients.
Description of the Benzodiazepine Service
Because learners were involved in the visits, visit times were extended. Initial visits were scheduled for 60 minutes, and follow-up visits were scheduled for 30 minutes. Electronic huddles within the EHR were used by the pharmacy team to flag patients on the schedule for the clinic staff to distribute patient screening tools during the rooming procedure, as pertinent. Screening tools included the Generalized Anxiety Disorder 7-item (GAD-7) scale, Insomnia Severity Index (ISI), and the Panic Disorder Severity Scale (PDSS) tool. The pharmacy team used the screening tools as part of their assessment of symptom control, as a means to ensure completeness of diagnoses and to track progress over time. All screening tools that were suggestive of a new diagnosis were discussed with the PCP for determination, given such diagnosis is not within the scope of practice for the clinical pharmacist. Given the patients' variable readiness to discontinue or change their benzodiazepine or implement nonpharmacological changes, some patients were seen over the course of multiple visits without changes. Motivational interviewing was implemented according to patients' individual stage of change as assessed by the transtheoretical model of change. 25 The pharmacy team collaboratively managed benzodiazepines and medications under CDTM. The CDTMs included evidence-based treatment algorithms and were developed by a team of pharmacists and physicians. Given the clinic is housed within the hospital, the CDTM was also approved by the hospital's pharmacy and therapeutics committee, as well as the clinic's medical director. Medication changes were made by the clinical pharmacist and were limited to those indicated in the CDTM. For needed changes that did not fall within the purview of the CDTM, the pharmacy team made recommendations and obtained approval from a PCP prior to making any changes. Efforts were made to discuss recommendations with the responsible PCP, but in situations where this was not possible, a partner PCP was consulted. Per the CDTM, all patients received education on nonpharmacological therapies (eg, avoiding stimulants and triggers, meditation, sleep hygiene, exercise) and were offered referrals to mental health specialists. Access to specialist care was dependent on patient payer source and availability. Per CDTM, the clinical pharmacist ordered pertinent laboratories as necessary to monitor for safe medication use and to screen for secondary causes of anxiety or sleep disturbance (eg, thyroid function, serum creatinine, liver function tests, electrolytes).
Patient follow-up was scheduled in 1 to 12 weeks via telephone or office visit. As needed, patients were proactively contacted via telephone to assess tolerability of medication changes and to expedite medication titration schedules. Inperson follow-up visits were scheduled to reassess symptom control. Patients were followed until symptoms were satisfactorily controlled, until the patient withdrew from medication management, or all therapeutic options were deemed exhausted by the pharmacist and PCP. All visit or phone proceedings were documented within the EHR, notifying the PCP of any updates or changes. Questions or disagreements between the pharmacist and PCP were collaboratively discussed.
Outcome Measures and Statistical Analyses
To understand the baseline need for the benzodiazepine service and potential areas for improvement, provider level data were collected by survey. Provider-level outcome measures included demographics, knowledge of appropriate benzodiazepine use, and provider prescribing confidence and attitudes. Provider demographics and characteristics were summarized by mean and standard deviation (SD) or frequency (N and %), and provider responses were summarized by frequency of response to each question and answer.
To assess the impact of the benzodiazepine service, efficacy and process measures were evaluated prospectively using standardized data collection forms. Patient-level data were collected from visits and the EHR. Outcome measures included proportion of appropriate prescriptions for benzodiazepines, symptom severity measured by validated screening instruments, rate of benzodiazepine discontinuation, proportion switched to safer benzodiazepines, proportion of visits with changes to benzodiazepine dose and frequency, and number of times safer nonbenzodiazepine medications were added or optimized. Patient stage of change according to the transtheoretical model of change was also assessed. Patient demographics and characteristics were summarized by mean and SD or frequency (N and %) for visits 1 and 2; not enough patients had completed more than 2 visits for data summarization at the end of this study to allow for the assessment of more than 2 visits.
To assess improvement in symptom scores, paired t tests were used to evaluate change in score among patients receiving the same screening tool at visits 1 and 2. The study was approved by the institutional review board.
Results

Baseline Survey Responses
Twenty-five (44%) of 57 PCPs responded to the survey assessing knowledge of benzodiazepine use. The respondents included physicians who had completed residency and/or fellowship (56%), resident physicians (40%), and 1 mid-level provider (4%). Of these, the primary professional roles included clinician (40%) and clinician-educator (48%). Of the 15 nonresident providers, the majority (60%) had between 10 and 14 years of practice. The number of half-day clinic sessions was evenly distributed between 1 and 8 clinic sessions. See Table 1 for PCP characteristics and Table 2 for responses to the survey items.
When asked about confidence in ability to diagnose or treat generalized anxiety disorder, sleep disorder, seizures, and panic disorder, providers scored a median of 7 to 8 on a 11-point Likert scale (0 ¼ not confident at all and 10 ¼ very confident), with the exception of treating seizure disorder, which had a median score of 5.
For generalized anxiety disorder, the majority of providers indicated they would initiate benzodiazepines never (20%) to rarely (44%) to occasionally (36%). For sleep disorder, the frequency of initiating benzodiazepines was similarly distributed for never, rarely, and occasionally. For seizures, most providers indicated they would never initiate benzodiazepines (64%), whereas for panic disorder, approximately half of the providers would initiate benzodiazepines occasionally.
Providers indicated it was appropriate to prescribe scheduled benzodiazepines as first-line therapy for certain indications, with 88% indicating alcohol withdrawal and 24% indicating bridging or adjunct therapy when initiating an antidepressant. As-needed use was commonly indicated as appropriate first-line therapy for panic disorder (64%) and alcohol withdrawal (60%).
When asked about preferred benzodiazepines for elderly patients, 40% of providers correctly identified lorazepam, 28% temazepam, and 16% oxazepam. Similarly, when asked about preferred benzodiazepines for liver dysfunction, 48% correctly identified lorazepam, 40% oxazepam, and 16% temazepam.
Based on responses to the knowledge-based question 3 of the survey, only 16% of providers selected the correct benzodiazepine and dosing frequency for generalized anxiety disorder, whereas 80% of providers correctly identified the correct benzodiazepine and dosing frequency for sleep disorder as indicated by knowledge-based question 4.
The results of the provider baseline survey indicated possible areas for improvement and opportunities for education on appropriate benzodiazepine use. Further, these results helped to justify the implementation of the pharmacist-physician collaborative benzodiazepine service.
Characteristics of Patients Seen in the Benzodiazepine Service
From January 28, 2015, to October 12, 2015, a total of 235 patients met study eligibility and had referrals pended for their respective PCP. Of the pended referrals, 89 (38%) were accepted and outreached to schedule an appointment with the benzodiazepine service. To date, 29 patients have been seen, totaling 44 visits in the benzodiazepine service. The mean age of patients was 58.4 years (standard deviation 12.7), 75.9% were women, 86.2% were Caucasian, and 100% were nonHispanic. Most patients had Medicare (48.3%) or commercial insurance (41.4%). Many patients had multiple indications for benzodiazepines. Nineteen (65.5%) patients used a benzodiazepine for generalized anxiety disorder, 19 (65.5%) for sleep disturbance, 2 (6.9%) for panic disorder, and 3 (10.3%) for other reasons including pain. Table 3 describes patient characteristics at baseline.
Medication Interventions
Of the 29 patients who attended at least 1 visit, 10 (34.5%) returned for 2 visits, 3 (10.3%) returned for 3 visits, and 2 (6.9%) returned for 4 visits. Selective serotonin reuptake inhibitors, serotonin norepinephrine reuptake inhibitors, and nonbenzodiazepine hypnotics were started or optimized in 15 (51.7%) patients at the first visit. Of the 10 patients with 2 visits, there were 8 (80%) interventions made to either start or optimize nonbenzodiazepine medications at the second visit. (64) 3 (12) 5 (20) 1 (4) summarizes the nonbenzodiazepine medication interventions at visits 1 and 2. At the first visit, there were 15 (51.7%) benzodiazepine changes made. These included discontinuing a benzodiazepine completely in 7 (24.1%) patients when down-titration was not necessary, decreasing dose or frequency of benzodiazepine in 6 (20.7%) patients, and switching to a more preferred benzodiazepine in 2 (6.9%) patients. At the second visit, there was only 1 benzodiazepine change made. Table 5 describes the benzodiazepine changes made at visits 1 and 2.
Symptom Improvement
For the 9 patients who completed a GAD-7 at visits 1 and 2, the mean decrease in score between visits was À2.0 (95% confidence interval [CI]: À3.57 to À0.43), which was statistically significant (P < .05). For patients who completed the ISI at visits 1 and 2, there was a nonsignificant (P > .05) mean decrease in score between visits of À0.7 (95% CI À3.31 to 1.91). There were too few responses for the Patient Health Questionnaire 9 and PDSS to assess the significance of change. Table 6 summarizes the change in symptom severity at visits 1 and 2.
Stages of Change According to the Transtheoretical Model of Change
At the first visit, 6 (20.7%) patients were in the precontemplation stage, 6 (20.7%) patients were in the contemplation stage, 8 (27.6%) patients were in the preparation stage, 8 (27.6%) patients were in the action stage, and 1 (3.4%) patient was in the maintenance stage. Of patients with at least 2 visits, 5 (50%) progressed to higher stages, 2 (20%) relapsed stages, and 3 (30%) neither progressed nor relapsed.
Discussion
Preliminary results of this study suggest that a collaborative pharmacist-physician team may improve appropriate use of high-risk benzodiazepines while improving anxiety and sleep disorder symptoms. Of the patients who attended these visits with the clinical pharmacy team, more than half benefitted from optimization of their benzodiazepine regimens. The majority of medication changes, both benzodiazepine and nonbenzodiazepine, were made during visit 1; however, this may be explained by fewer patients with more than 1 visit. The significant improvements in anxiety symptom severity over 2 visits suggest such a collaborative model to minimize high-risk benzodiazepine use may also be beneficial in improving treatment efficacy. Although the improvement seen in sleep disturbance severity was not significant, the lack of regression is encouraging. The early efficacy results are promising, given the goal was to minimize benzodiazepine use when possible and benzodiazepines are known to be highly effective and often perceived to be most effective by patients. Larger sample sizes are needed to fully understand the impact of this collaborative service on symptom severity for anxiety, sleep, and depression.
Limitations of these findings include its observational design, a small patient population, and a limited number of follow-up visits to assess change. The small sample size is partly due to a slow roll out, provider acceptance of referral orders, and patient acceptance of the service. Some patients who expressed disinterest in the benzodiazepine service were ambivalent about the service, indicating they were uninterested in making any changes to their therapy or did not think the appointment would be helpful. Some expressed confusion about the role of the pharmacist despite thorough explanations during outreach calls. Although many patients scheduled appointments, many patients cancelled or did not show up to their appointments. Although the cancellation and no show rate was not collected, it was perceived to be noticeably higher than for other patient visits with the pharmacy team. Follow-up with patients who cancelled or did not show up to their appointments indicated some patients no longer wanted to be seen by the benzodiazepine service. Outreach calls were limited by a high proportion of patients who did not answer attempts to reach them or did not return messages. For patients who had been seen for 1 visit, ensuring follow-up for subsequent visits was also a challenge. Some reported they did not think they needed a second visit or that they did not want their medications changed. Given patients' variable stages of change related to their benzodiazepine use and willingness to implement nonpharmacological therapy, patient stage of change according to the transtheoretical model of change was assessed. Although few patients had more than 1 visit, half of the patients with 2 visits advanced by at least 1 stage of change, while 2 patients regressed. These findings may suggest more than 1 visit is beneficial for these patients who may initially be unreceptive to medication changes, including optimization of their benzodiazepine.
Provider acceptance of referral orders for the benzodiazepine service was not as high as expected, but may be because providers may not fully understand the scope of the clinical pharmacist, despite being integrated in the clinic for 4 years. Further, referral acceptance may be lower than expected due to fear of scrutiny regarding medication decisions or unfamiliarity with ideal prescribing of benzodiazepines. Although the educational session attempted to target aspects of benzodiazepine use that were less understood by PCPs, not all providers attended the faculty meeting where the educational session occurred. A follow-up survey is planned to reassess provider understanding of appropriate benzodiazepine use and see if the formal or informal education resulting from the benzodiazepine service has influenced the knowledge.
These early results support the benefit of the collaborative benzodiazepine service on patient outcomes and safe medication use. The service is ongoing and will be reassessed when additional patients have been seen over the course of more visits. Additional studies are also planned to better understand patient and provider characteristics that may predict acceptance or engagement with the benzodiazepine service and compared to other clinical pharmacy services offered, such as hypertension and pain management.
Conclusion
This study highlights the benefits of collaborative team-based models of care that include clinical pharmacists in primary care to assist with optimizing high-risk benzodiazepine use. The findings from this study suggest that patients may benefit from improved medication use and symptom improvement, but additional studies with more subjects and a comparison group are needed to validate these preliminary findings. Further studies should also assess provider satisfaction and perceived impact on workload.
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